Scholars Central

Conference abstractPublished 19 Sep 2019

Epilepsy spectrum associated to anti-glutamic acid decarboxylase antibody

Authors: Ines Bedoui

Military Hospital of Tunis, Tunisia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Anti-glutamic acid decarboxylase antibodies (GAD), initially described in type 1 diabetics, have been recently identified in some patients with epilepsy. Glutamic acid decarboxylase (GAD) antibody-associated encephalitis causes both acute seizures and chronic epilepsy with predominantly temporal lobe onset. The incidence of GAD antibody related epilepsy could be much higher than commonly believed. Objective: The purpose of our work was to review the physiology, pathology, clinical presentation and management of GAD associated epilepsy. Results: We included in our study 15 patients, 11 women and 4 men. The mean age of the beginning of the epilepsy was 41, 3±6 years old. All of them had pharmaco-resistant epilepsy. Neuro-cognitive disorders were found in 13 cases and movement disorders in 11 cases. A moderated lymphocytic pleocytosis was found in cerebro-spinal fluid (CSF) examination in 10 patients. Anti GAD antibodies were positive in the blood in all patients, and in CSF in 8 cases. Poorly responsive to antiepileptic drugs and moderately responsive to immune therapy with steroids, intravenous immunoglobulin and plasma exchange are obtained in all patients. Discussion and Conclusions: Imaging and CSF evidence of inflammation along with typical clinical presentations, such as adult onset temporal lobe epilepsy (TLE) with unexplained etiology, should prompt testing anti GAD antibodies. Anti-GAD65 mediated epilepsy is often poorly responsive to antiepileptic drugs and only moderately responsive to immune therapy with steroids, intravenous immunoglobulin, or plasma exchange. Long-term treatment with more aggressive immunosuppressant such as rituximab and/or cyclophosphamide is often necessary than current immunosuppressive approaches.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Alzheimers Disease & Parkinsonism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Alzheimers Disease & Parkinsonism
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Ines Bedoui”